Yongling Ji
About
Yongling Ji is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology.
According to data from OpenAlex, Yongling Ji has authored 33 papers receiving a total of 323 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Pulmonary and Respiratory Medicine, 16 papers in Surgery and 13 papers in Oncology. Recurrent topics in Yongling Ji's work include Esophageal Cancer Research and Treatment (16 papers), Gastric Cancer Management and Outcomes (11 papers) and Lung Cancer Diagnosis and Treatment (10 papers). Yongling Ji is often cited by papers focused on Esophageal Cancer Research and Treatment (16 papers), Gastric Cancer Management and Outcomes (11 papers) and Lung Cancer Diagnosis and Treatment (10 papers). Yongling Ji collaborates with scholars based in China, Netherlands and Singapore. Yongling Ji's co-authors include Xianghui Du, Liming Sheng, Guoqin Qiu, Xia Zhou, Dan Su, Wumin Dai, Yu Chong, Xiaojiang Sun, Mengyuan Chen and Yang Yang and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and BMC Medicine.
In The Last Decade
Yongling Ji
30 papers receiving 319 citations
Peers
Yongling Ji
Xianghui Du China
Ahmet Demirkazık Türkiye
Kaoru Kaseda Japan
Angelika Terbuch Austria
Yakup Bozkaya Türkiye
Xiu-Yu Cai China
Guoqin Qiu China
Suna Çokmert Türkiye
Laurent Taillade France
Jean Torrisi United States
Citations per year, relative to Yongling Ji Yongling Ji (= 1×)
peers
Xianghui Du
Countries citing papers authored by Yongling Ji
Since
Specialization
Citations
This map shows the geographic impact of Yongling Ji's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yongling Ji with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yongling Ji more than expected).
Fields of papers citing papers by Yongling Ji
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Yongling Ji. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yongling Ji. The network helps show where Yongling Ji may publish in the future.
Co-authorship network of co-authors of Yongling Ji
This figure shows the co-authorship network connecting the top 25 collaborators of Yongling Ji. A scholar is included among the top collaborators of Yongling Ji based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yongling Ji. Yongling Ji is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Zhang, Zhen, Haixia Shen, Jian Zeng, et al.. (2025). Voxel-level radiomics and deep learning for predicting pathologic complete response in esophageal squamous cell carcinoma after neoadjuvant immunotherapy and chemotherapy. Journal for ImmunoTherapy of Cancer. 13(3). e011149–e011149.
2.
Wang, Wenjing, et al.. (2024). Targeting the MET gene: unveiling therapeutic opportunities in immunotherapy within the tumor immune microenvironment of non-small cell lung cancer. Therapeutic Advances in Medical Oncology. 16. 12735469–12735469.
3.
Yang, Yang, Xiufeng Cao, Mengyuan Chen, et al.. (2024). Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable esophageal squamous cell carcinoma: A pooled analysis of randomized clinical trials. Radiotherapy and Oncology. 200. 110517–110517.
4.
Chen, Long, Ou Jiang, Hong Ge, et al.. (2024). TQB2450 with or without anlotinib as maintenance treatment in subjects with locally advanced/unresectable non-small cell lung cancer that have not progressed after prior concurrent/sequential chemoradiotherapy (R-ALPS): study protocol for a randomized, double-blind, placebo-controlled, multicenter phase III trial. Translational Lung Cancer Research. 13(10). 2828–2837.
5.
Chen, Mengyuan, Runhua Li, Yue Kong, et al.. (2024). Rational and design of prophylactic cranial irradiation (PCI) and brain MRI surveillance versus brain MRI surveillance alone in patients with limited-stage small cell lung cancer achieving complete remission (CR) of tumor after chemoradiotherapy: a multicenter prospective randomized study. BMC Cancer. 24(1). 429–429.
6.
Shen, D. S., Runzhe Chen, Yongling Ji, et al.. (2024). Safety and short-term outcomes of esophagectomy after neoadjuvant immunotherapy combined with chemotherapy or chemoradiotherapy for locally advanced esophageal squamous cell cancer: analysis of two phase-II clinical trials. Journal of Gastrointestinal Oncology. 15(3). 841–850.
7.
Appelt, Ane, Yongling Ji, Ji Zhu, et al.. (2024). Improved prognostication of overall survival after radiotherapy in lung cancer patients by an interpretable machine learning model integrating lung and tumor radiomics and clinical parameters. La radiologia medica. 130(1). 96–109.
8.
Shen, Haixia, Jin Wang, Yang Yang, et al.. (2024). Safety and feasibility of neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced esophageal squamous cell carcinoma: a prospective single-group phase II clinical study. Journal of Thoracic Disease. 16(10). 7029–7041.
9.
Xiang, Qian, Zhuo Chen, Xuming Ji, et al.. (2024). Qingfei mixture modulates the immune responses in lung cancer through modulating mTOR signaling and gut microbiota-derived short-chain fatty acids. Heliyon. 10(8). e29404–e29404.
10.
Kong, Yue, Mengyuan Chen, Youhua Jiang, et al.. (2024). Radiotherapy for patients with locally advanced esophageal squamous cell carcinoma receiving neoadjuvant immunotherapy combined with chemotherapy. Scientific Reports. 14(1). 16495–16495.
11.
Zhang, Jie, Yiwei Yang, Min Fang, et al.. (2023). A research on the improved rotational robustness for thoracic organ delineation by using joint learning of segmenting spatially‐correlated organs: A U‐net based comparison. Journal of Applied Clinical Medical Physics. 24(11). e14096–e14096.
12.
Zeng, Jian, Cheng Liu, Wei Shen, et al.. (2023). Using clinical and radiomic feature–based machine learning models to predict pathological complete response in patients with esophageal squamous cell carcinoma receiving neoadjuvant chemoradiation. European Radiology. 33(12). 8554–8563.
13.
Xu, Liwei, Youhua Jiang, Yongling Ji, et al.. (2022). Crosstalk between the gut microbiome and clinical response in locally advanced thoracic esophageal squamous cell carcinoma during neoadjuvant camrelizumab and chemotherapy. Annals of Translational Medicine. 10(6). 325–325.
14.
Yang, Yang, Mengyuan Chen, Yongling Ji, et al.. (2022). Treatment Patterns and Outcomes of Elderly Patients With Potentially Curable Esophageal Cancer. Frontiers in Oncology. 12. 778898–778898.
15.
Zhu, Xuan, et al.. (2020). Video-Assisted Thoracoscopic Lobectomy Versus Stereotactic Body Radiotherapy Treatment for Early-Stage Non-Small Cell Lung Cancer: A Propensity Score-Matching Analysis. Frontiers in Oncology. 10. 585709–585709.
16.
Ji, Yongling, et al.. (2016). A phase I dose escalation study of S-1 with concurrent radiotherapy in elderly patients with esophageal cancer. Journal of Thoracic Disease. 8(3). 451–458.
17.
Qiu, Guoqin, Xianghui Du, Liming Sheng, et al.. (2016). Differences in displacement of the proximal and distal ends of mid-upper thoracic esophageal squamous cell carcinoma. Molecular and Clinical Oncology. 5(1). 143–147.
18.
Qiu, Guoqin, Xianghui Du, Xia Zhou, et al.. (2016). Prophylactic cranial irradiation in 399 patients with limited-stage small cell lung cancer. Oncology Letters. 11(4). 2654–2660.
19.
Ji, Yongling, Liming Sheng, Xianghui Du, Guoqin Qiu, & Dan Su. (2014). Elevated platelet count is a strong predictor of poor prognosis in stage I non-small cell lung cancer patients. Platelets. 26(2). 138–142.
20.
Xu, Yaping, Shenglin Ma, Yongling Ji, et al.. (2010). Concomitant chemoradiotherapy using pemetrexed and carboplatin for unresectable stage III non-small cell lung cancer (NSCLC): Preliminary results of a phase II study. Lung Cancer. 72(3). 327–332.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Xianghui Du Breakdown of academic impact, for papers by Ahmet Demirkazık Breakdown of academic impact, for papers by Kaoru Kaseda Breakdown of academic impact, for papers by Angelika Terbuch Breakdown of academic impact, for papers by Yakup Bozkaya Breakdown of academic impact, for papers by Xiu-Yu Cai Breakdown of academic impact, for papers by Guoqin Qiu Breakdown of academic impact, for papers by Suna Çokmert Breakdown of academic impact, for papers by Laurent Taillade Breakdown of academic impact, for papers by Jean Torrisi